Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, one of the country's leading life-sciences companies, announced today that William (Bill) Dodero, its current Vice President and Global Head of Litigation, will become the company's new U.S. General Counsel and Senior Vice President, as well as a member of the U.S. Country Leadership Team. Dodero succeeds Scott Partridge who decided to depart Bayer at the end of the year after 16 years at Monsanto and Bayer to focus on dispute resolution representation an

Bayer Names William Dodero New U.S. General Counsel Beginning January 2023

LEVERKUSEN, Germany--(BUSINESS WIRE)--Bayer has completed the sale of its Environmental Science Professional business to the international private equity firm Cinven, after the two companies had entered into a corresponding agreement in March. The conditions for closing the transaction – including the receipt of regulatory approval – have now been met. The purchase price for the business, which generated sales of approximately 600 million euros in 2021, amounts to 2.6 billion U.S. dollars. “We

Bayer Completes Sale of Its Environmental Science Professional Business to Cinven

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Fund, the philanthropic arm of Bayer in the U.S., is proud to announce today that it has provided a total of $8.2M in grant funding, spanning across 2,085 organizations, in the first half of 2022. As part of Bayer's broader vision of ensuring Health for All, Hunger for None, each Bayer Fund grant goes towards programs that help solve some of the country's – and world's – biggest challenges, including access to food and nutrition, STEM education and health

Bayer Fund Announces $8.2M in Donations to U.S. Nonprofit Organizations During First Half of 2022

Anglo American Platinum Ltd

Freyr Battery Inc

Poshmark

Provident Financial Holdings

NuScale Power Corp

Woodside Energy Group Ltd

In arguably most cases, investors should concentrate the bulk of their portfolio on high-quality names, irrespective of catchy marketing schemes like under-$20 sleeper stocks to buy. Usually, comfort (and confidence) exists in the consensus of the crowd.

7 Under-$20 Sleeper Stocks to Buy Before Wall Street Wakes Up

WHIPPANY, N.J.--(BUSINESS WIRE)--World Contraception Day is celebrated around the globe as a day to bring focus to the importance of family planning and access to birth control. To commemorate this year's celebration, Bayer is pleased to announce a new round of grant funding representing additional investment in the Community Health Awards program, a collaboration with humanitarian group Direct Relief. The Direct Relief program provides funding to help address health disparities and pressing co

Bayer Announces Further Investment in Direct Relief Community Health Awards Program

Professional teams are well known for “eating” bad contracts, and now it looks like German pharmaceutical company Bayer AG ( XTER:BAYN , Financial) is following suit. Rumors abound that CEO Werner Baumann is going to be asked to turn in his playbook quickly.

Bayer Rumored to Be Bidding Early Goodbye to CEO

Bayer AG and some of its subsidiaries agreed to pay $40 million to settle claims over its alleged use of kickbacks and false statements related to the drugs Trasylol, Avelox and Baycol, the U.S. Department of Justice said on Friday.

U.S. says Bayer to pay $40 million to resolve whistleblower lawsuits

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that it received approval from the United States (U.S.) Food and Drug Administration (FDA) for an update to the label for KERENDIA® (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA), to include findings from the FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).1 FIGARO-DKD is the first contemporary Phase III CV outcomes trial with the

Bayer's KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes

Enel SpA

LM Ericsson Telefon

Sirius XM Holdings Inc

Takeda Pharmaceutical

Universal Technical Institute

Vale S.A.

Generally speaking, you want to focus your investments on companies with strong fundamentals, not just on companies that meet a certain price metric, such as stocks under $15. However, certain public firms offer compelling narratives that patient buyers can hold for the long run.

7 Stocks Under $15 to Buy and Hold Forever

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present key scientific research in oncology at the upcoming ESMO Congress 2022 from September 9-13, 2022. Data will highlight Bayer's commitment to advancing unmet needs in prostate cancer, providing expertise in precision medicine, and working on immunotherapy combinations, including company-sponsored and collaborative research studies. New Phase III ARASENS trial data for NUBEQA® (darolutamide) will be presented on quality of life and patient-releva

Bayer Demonstrates Commitment to Advancing Oncology by Showcasing New Data From Innovative Science at ESMO Congress 2022

Bristol-Myers

Bristol Myers and Johnson & Johnson's blood thinner fell short of expectations in stroke patients, leading BMY stock to crumble on Monday. The post Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner Flops appeared first on Investor's Business Daily.

Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner Flops

Johnson & Johnson

Investors should keep an eye on developments at the European Society of Cardiology meeting, which is underway in Barcelona. News about a new type of heart drug being tested by Bristol-Myers Squibb Co. ( BMY , Financial), Johnson & Johnson ( JNJ , Financial) and Bayer AG ( XTER:BAYN , Financial) could potentially move the shares of the three pharmaceutical giants.

Bristol-Myers, J&J and Bayer Presenting Key Study Results at Heart Meeting

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Bayer Aktiengesellschaft (BAYRY) is a Top-Ranked Value Stock: Should You Buy?

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present a range of new clinical data at the European Society of Cardiology's 70th Annual Scientific Session (ESC.22) from August 26-29. Three late-breaking abstracts will be presented including data on the nonsteroidal mineralocorticoid receptor (MR) antagonist, KERENDIA® (finerenone),1 and the investigational oral Factor XIa inhibitor, asundexian. These data highlight Bayer's ongoing commitment to patients with cardiovascular (CV) and kidney diseases

Bayer to Present Data From Cardiovascular Portfolio, Including a Late-Breaking Presentation From FIDELITY for KERENDIA® (finerenone) and New Phase IIb Data From PACIFIC Trial Program for the Oral Factor XIa Inhibitor asundexian

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a leader in women's healthcare, announced today that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) that extends the duration of use for its market leading intrauterine device (IUD) Mirena® (levonorgestrel-releasing intrauterine system) 52 mg by one more year, making it available to prevent pregnancy for up to eight years.1 The approval is based on results from a Phase 3 extension trial evaluating the effic

FDA Label Update Reflects Bayer's Commitment to Providing Options for Long-acting Contraception

Air Liquide SA

Allianz SE

BASF SE

Banco Bilbao Vizcaya Argentaria

Deutsche Boerse AG

Infineon Technologies AG

ING Groep NV

Banco Santander

Bridgewater Associates, one of the biggest hedge funds in the world, has seemingly walked away from its big short bet

Ray Dalio's Bridgewater cuts European short bet to under $1 billion

GlaxoSmithKline

Dr. Reddy's Labs

The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.

Plaintiff in first Zantac lawsuit set for trial drops case

Germany's Bayer said it has decided to continue supplying Russia with essential agricultural inputs, reversing course from comments made in March that supplies for 2023 would be contingent on Russia stopping its attacks on Ukraine.

Bayer says it will continue supplying Russia with agricultural inputs

Agricultural seeds and chemicals maker Bayer AG on Monday launched a digital farming platform that it says will help U.S. growers enact environmentally friendly practices and connect them with companies seeking more sustainable food, feed and biofuel ingredients.

Bayer launches sustainable agriculture hub to connect U.S. farmers, food and fuel makers

ST. LOUIS--(BUSINESS WIRE)--Today, Bayer announced the launch of ForGround, a farmer-first digital platform that will transform the way farms of all sizes can more easily make the transition to sustainable agricultural practices. ForGround offers growers tools, resources, discounts, as well as and the potential to earn revenue through the Bayer Carbon Program7 for the adoption of regenerative practices and to connect with businesses looking to advance their sustainability and carbon goals. Base

Bayer Launches ForGround, a Unique Sustainable Agriculture Platform Focused on Transforming How Farmers and Companies Collaborate

Bayer on Friday welcomed a decision by an arbitration court to dismiss a claim by BASF that it overpaid for assets sold by Bayer to secure antitrust clearance for the takeover of Monsanto.

Bayer welcomes ruling against BASF claim on seed businesses

Mexican President Andres Manuel Lopez Obrador said on Tuesday that the chief executive of German diversified group Bayer Werner Baumann said the firm is interested in continuing to invest in Mexico in pharmaceuticals and food supplies.

Mexican President says Bayer interested in continuing to invest in country

In Q2 2022, Bayer delivered strong results across all of the company's divisions. Bayer generated revenues of EUR 12.8 billion (+9.6% year over year), and EBITDA before special items jumped by more than 30% to EUR 3.3 billion.

Bayer: Bullish Thesis Confirmed

Bayer Aktiengesellschaft (OTCPK:BAYZF) Q2 2022 Results Conference Call August 4, 2022 9:00 AM ET Company Participants Oliver Maier - Head, IR Werner Baumann - CEO Wolfgang Nickl - CFO Rodrigo Santos - Head, Crop Science Stefan Oelrich - Head, Pharmaceuticals Heiko Schipper - Head, Consumer Health Conference Call Participants James Quigley - Morgan Stanley Michael Leuchten - UBS Peter Verdult - Citigroup Vincent Andrews - Morgan Stanley Sachin Jain - Bank of America Richard Vosser - JPMorgan Tony Jones - Redburn Laurent Favre - BNPP Laurent Favre - BNP Paribas Exane Keyur Parekh - Goldman Sachs Sebastian Bray - Berenberg Jo Walton - Credit Suisse Falko Friedrichs - Deutsche Bank Operator Good afternoon ladies and gentlemen, thank you for standing by. Welcome to Bayer's Investor and Analyst Conference Call on the Second Quarter 2022 Results.

Bayer Aktiengesellschaft (BAYZF) CEO Werner Baumann on Q2 2022 Results - Earnings Call Transcript

Bayer (BAYRY) beats estimates for both earnings and revenues in the second quarter of 2022.

Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q2

News for Bayer AG Stock (BAYRY)